This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
The Smart Future: Will Robotics Call the Shots Post Coronavirus?
by Zacks Equity Research
Robots are assisting in surprising ways on the COVID frontline. With their pivotal role in battling the coronavirus, robotics revolution is swiftly gaining momentum and soon might be the new normal.
Zimmer (ZBH) Up 18.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares Morningstar MidCap Value ETF (JKI) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for JKI
Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid
by Zacks Equity Research
Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.
Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.
Zimmer Biomet (ZBH) Beats Q1 Earnings Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 22.30% and -0.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
How Hard Will Coronavirus Hit Zimmer Biomet (Zbh) Q1 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) may have registered improved performances within its Hips and Knees arms due to the nature of the businesses.
Here's Why You Should Add Zimmer Biomet to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Zimmer Biomet (ZBH) on its strong segmental and international results in the fourth quarter of 2019.
Zimmer Biomet Grows on Strong Emerging Market, Innovation
by Zacks Equity Research
Zimmer Biomet (ZBH) solidifies its foothold in the emerging markets on strong operational and sales performance.
Should iShares Morningstar Mid-Cap Value ETF (JKI) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKI
ZBH or MDT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Robotics & AI Make Inroads in HealthCare: Stocks to Benefit
by Sreoshi Bera
Robotics and AI make rapid advancement in the field of healthcare. Here are five stocks that you can bet on.
Align Technology to Acquire exocad in Digital Dentistry Space
by Zacks Equity Research
This acquisition is expected to boost Align Technology's (ALGN) portfolio of Invisalign and iTero digital solutions.
Why Is Zimmer (ZBH) Down 12.5% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Products Industry Outlook: Growth Prospects Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.
Here's Why You Should Add Zimmer (ZBH) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.
Zimmer Biomet (ZBH) Is Up 0.07% in One Week: What You Should Know
by Zacks Equity Research
Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZBH or MDT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Zimmer Biomet (ZBH) benefits from strong sales growth across all geographies as well as segmental strengths at CER.
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 1.77% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.
What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.
Zimmer Biomet (ZBH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.